OpenAI mulls investing in brain implant startup to rival Musk’s Neuralink- reports

OpenAI and co-founder Sam Altman are backing Merge Labs, a new brain-computer interface (BCI) startup, to directly compete with Elon Musk’s Neuralink. Merge Labs is reportedly raising $250 million at an $850 million valuation, with significant capital expected from OpenAI, intensifying the ongoing rivalry between Altman and Musk across the AI and BCI sectors. This strategic investment signals increased competition in the nascent BCI market, where Neuralink currently holds a leading position with a $9 billion valuation.

Analysis

OpenAI and its co-founder Sam Altman are reportedly backing a new brain-computer interface (BCI) startup, Merge Labs, signaling a direct competitive challenge to Elon Musk's Neuralink. According to reports, Merge Labs is in early discussions to raise $250 million at an $850 million valuation, with a significant portion of the capital anticipated from OpenAI. This development intensifies the well-documented rivalry between Altman and Musk, extending their competition from the core artificial intelligence space—where OpenAI competes with Musk's xAI—into the nascent BCI sector. The move is significant as it introduces a formidable, well-capitalized challenger into a market where Neuralink is the current front-runner, having recently raised $650 million at a $9 billion valuation. The investment underscores a broader bet that advancements in AI will be critical to unlocking the potential of BCI technology. While Neuralink has achieved a key milestone with a human implant in 2024, it also faces public criticism over scientific and ethical practices, potentially creating a strategic opening for a competitor like Merge Labs.

Key Decisions for Investors

• Investors with exposure to venture capital should monitor the BCI sector for an acceleration in funding and innovation, as the entry of a major AI player like OpenAI validates the market's long-term potential.
• The intensified rivalry between Altman and Musk is now a primary catalyst in both the AI and BCI domains; portfolio managers should assess the potential for this competition to drive both rapid technological progress and heightened capital burn rates for the private entities involved.
• While the key companies are private, investors should identify potential long-term second-order effects on publicly traded firms in the medical device, semiconductor, and software industries that could supply or be disrupted by BCI technology breakthroughs.
• Given that Neuralink faces ethical criticism, investors should consider the ESG (Environmental, Social, and Governance) risk profile of the emerging BCI market and favor entities that demonstrate more transparent scientific and ethical standards.